Immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CART cell therapy
Cancer Research
; 82(12), 2022.
Article
in English
| EMBASE | ID: covidwho-1986488
ABSTRACT
Introduction:
Patients with hematologic malignancies are at an increased risk of morbid/mortality from COVID-19. Our prospective clinical study evaluated immune responses to COVID-19 mRNA vaccines in patients with B-cell lymphoma who had received CD19-directed chimeric antigen receptor (CAR) T cell therapy.Methods:
We measured SARS-CoV-2 neutralizing activity of plasma from 18 patients and 4 healthy controls (HC) and antibody titers against viral spike proteins (S1, S2, RBD) including their delta variants using an enzyme-linked immunoassay (ELISA). We measured B cell subpopulations in the patients' blood using flow cytometry.Results:
We found that the peripheral blood plasma from 3/4 HCs showed substantial SARS-CoV-2 neutralizing activity already at 4 weeks after the first dose of COVID-19 mRNA vaccine while none of the CD19 CART patients evidenced any antibody-mediated neutralizing activity at the same point in time. At 4 weeks after receiving the second dose of the vaccine, all 4 HCs showed complete neutralizing activity. In marked contrast, only 1 of 14 CART patients evidenced any relevant antibody-mediated SARS-CoV-2 neutralizing activity. Assessing whether a globally insufficient antibody-mediated immunity was the underlying cause of the lack of a response to the COVID-19 vaccine in our CART patients, we found that IgG antibody levels against common microbial and viral antigens like influenza, Epstein-Barr virus (EBV), Cytomegalovirus (CMV), and tetanus toxoid, were comparable to those observed in HCs. However, while at 4 weeks post second dose of the vaccine the HCs showed high levels of vaccine-induced IgG antibody titers against all the viral spike proteins (S1, S2, RBD), including the delta variants of the S1 and RBD proteins, the vast majority of our CART patients did not evidence any SARS-CoV-2-specific antibodies. Importantly, a third booster vaccination did not lead to an improvement in the antiviral immunity in the 4 CART patients analyzed. When we assessed B cell subpopulations in the blood of patients and HCs, we found that prior treatments had completely eradicated all CD19+/CD20+ B cells in the patients while numbers of long-lived memory plasma cells were comparable to those of HCs.Conclusions:
In this study, 17 of 18 patients with lymphoma who received CD19 CART therapy had very poor immunoreactivity to 1-3 doses of mRNA-based COVID-19 vaccines. Importantly, antibody responses to common recall antigens were preserved, suggesting impaired immune response primarily against novel antigens like SARS-COV-2. This lack of immunoreactivity against novel antigens was probably based on the eradication of earlier-stage B cell subpopulations after treatment with anti-CD19 and anti-CD20 immunotherapies.
antivirus agent; CD19 antigen; CD20 antibody; endogenous compound; immunoglobulin G antibody; messenger RNA; SARS-CoV-2 vaccine; tetanus toxoid; virus antigen; virus spike protein; adult; antibody response; antibody titer; B lymphocyte; B lymphocyte subpopulation; cancer patient; cell therapy; clinical article; conference abstract; controlled study; coronavirus disease 2019; Cytomegalovirus; drug therapy; enzyme activity; enzyme linked immunosorbent assay; Epstein Barr virus; female; flow cytometry; gene expression; human; human cell; human tissue; immune response; immunoreactivity; immunotherapy; influenza; lymphoma; male; memory; nonhuman; plasma cell; plasmacytoma; prospective study; recall; revaccination; SARS-CoV-2 Delta; Severe acute respiratory syndrome coronavirus 2; vaccination; virus immunity
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Cancer Research
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS